ABSTRACT: A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481. The compound showed robust reductions of Aβ 1−42 and Aβ 1−40 in the plasma, brain, and cerebrospinal fluid of mice and rats. Consistent with the γ-secretase modulator mechanism, increases in Aβ 1−37 and Aβ 1−38 were observed, with no change in the total amount of Aβ 1−x produced. No Notch-based toxicity was observed, and the overall preclinical profile of BMS-932481 supported its further evaluation in human clinical trials.
A lzheimer's disease (AD) is a neurodegenerative disorder of the elderly. Progressively worsening symptoms include memory loss, difficulty with language and abstract thinking, difficulty with familiar tasks, and impaired recognition of family and friends. Death occurs on average 10 years after initial diagnosis. The prevalence of AD in the U.S. is ca. 5.7 million people and is expected to grow significantly in the coming decades. 1 The pathology of AD precedes the onset of symptoms by a decade or more and is characterized by the deposition of amyloid plaques and neurofibrillary tangles in the brain. The current standard of care, acetylcholinesterase inhibitors and an NMDA antagonist, provides minimal and temporary benefit, and does not prevent progression of the disease. Much of AD drug discovery has focused on reducing the production of the Aβ peptides, which produce the characteristic amyloid plaques found in the brain. Inhibitors of the enzymes responsible for Aβ production, beta-and gamma-secretase (GS), have entered clinical trials but have failed to achieve commercialization. Recently, several late-stage trials of beta-secretase (BACE) inhibitors failed to achieve clinical success. Merck has announced that the study of verubecestat in prodromal AD patients was suspended following an interim safety analysis that predicted an inadequate benefit/risk ratio, 2 and AstraZeneca/Lilly has terminated the study of lanabecestat in AD patients with either mild cognitive impairment or mild dementia 3 because it was unlikely to meet the primary end points of the trial. 4 Likewise, despite the enormous effort expended to advance six different gamma-secretase inhibitors (GSIs) into Phase II/III clinical trials, these agents failed in part due to toxicity stemming from suppressing the proteolysis of other GS substrates, most notably Notch. 5 An alternative drug mechanism, gamma-secretase modulators (GSMs), seeks to exploit the differing potential of the several endogenous Aβ 1−x peptide species to aggregate to form neurotoxic oligomers. Specifically, GSMs shift the distribution of gamma secretase cleavage products away from the longer Aβ 1−42 and Aβ 1−40 peptides to the shorter forms Aβ 1−38 and Aβ 1−37 . 6 The shorter species are less lipophilic, less aggregation-prone, and less neurotoxic than aggregates of Aβ 1−42 and, in fact, may play a direct role in hindering the aggregation of Aβ 1−42 . 7 Importantly, toxicity arising from the suppression of the Notch signaling pathway is avoided by the GSM mechanism because GS activity is not inhibited. Thus, GSMs offer an attractive alternative disease-modifying mechanism to avoid GSI toxicity.
Efforts in our laboratories to discover a GSM began with a screen 8 of the BMS compound collection, which identified triazine 1 (Figure 1 ). The IC 50 for Aβ 1−42 lowering was 120 nM in our primary H4 cell-based assay. 9 No effect was seen on total Aβ 1−x formation, whereas increased levels of Aβ 1−37 and Aβ 1−38 were observed in experiments using urea gel Western blotting (data not shown). Taken together, these results firmly establish 1 as a GSM. The central triazine core (C ring, Figure  1 ), flanked by a triazolyl anisole biaryl moiety (A−B rings) and an aromatic group (E ring), was topologically similar to other GSMs known in the patent literature. However, both the Eisai cinnamide 10 and Schering−Plough alkenyl oxadiazole 11 chemotypes possessed a methine linker between the B-and C-rings, so the aniline NH linking the B and C rings in 1 was unique in the public literature at that time. 12 Additionally, the triazine 4-NHMe substituent represented an additional vector for potential optimization.
Compound 1 was rapidly modified to incorporate a 4-methylimidazole A-ring and benzyl E-ring to form compound 2, which was potent (Aβ 1−42 IC 50 = 31 nM) in our primary assay. Triple transgenic LaFerla mice, 13 which exhibit accelerated plaque and tangle pathology resulting from the presence of the APP Swedish, MAPT P301L, and PSEN1M146V mutations, were orally dosed at 30 mg/kg with compound 2 in a solution formulation. At 3 h postdose, a 32% reduction in brain Aβ 1−42 was observed, with a brain to plasma concentration ratio (B/P) = 0.47. Compound 2 exhibited liabilities that would need to be addressed in subsequent compounds, specifically a short half-life as a consequence of ubiquitous metabolism, potent hERG inhibition, and potent and time-dependent CYP3A4 inhibition. After extensive structure−activity relationship exploration, we identified and integrated two structural modifications leading to pyrimidine 3. First, the change from a triazine to a pyrimidine C-ring core permitted the fusion of an additional carbocyclic ring (D-ring, Figure 1) , which restricted the position of the aryl E-ring relative to the core. Second, replacement of the 4-methylimidazole A-ring with 4-chloroimidazole provided an improvement in both potency and CYP3A4 inhibition profile. Together, these features increased the potency of 3 vs 2 by an order of magnitude (IC 50 = 2.0 nM). Consistent with its high potency relative to 2, compound 3 demonstrated an in vivo pharmacologic response in multiple species. In LaFerla mice, a 30 mg/kg oral dose of 3 reduced the level of brain Aβ 1−42 by 86% after 3 h, and in Harlan Sprague−Dawley rats, a 10 mg/kg oral dose reduced Aβ 1−42 by 59% 3 h postdose. The corresponding plasma concentrations were 2.1 μM in LaFerla mice and 1.7 μM in rat, and the B/P ratio in rats was 0.38. Furthermore, the metabolic profile of 3 was improved over 2, with 96% of parent compound remaining after a 10 min incubation with human liver microsomes, 14 while in vitro biotransformation assays showed that metabolism was confined to N-demethylation and monohydroxylation of the D-ring. An AUC 0−24h of 7.6 μM·h elicited our targeted 25% AUC 0−24h reduction 15 of rat brain Aβ 1−42 . Allometric scaling of the results from similar experiments in dog and cynomolgus monkey predicted a human dose for 25% lowering of Aβ 1−42 of 90 mg QD (1.3 mg/kg), aided by the oral bioavailability across species (49%, 64%, and 44% in rat, dog, and cynomolgus monkey, respectively).
Given the improvements in PK/PD relative to 2, we profiled 3 for safety. Patch-clamp electrophysiology revealed potent inhibition of the hERG ion channel (IC 50 = 200 nM). However, the low free fraction of 3 (0.1%) contributed to a satisfactory predicted safety margin with regard to hERGmediated cardiac events since the QRT elongation effects of hERG inhibition are driven by the free-drug concentration. This prediction was confirmed by a rabbit telemetry study, which demonstrated a 40-fold safety margin vs the hERG NOAEL of 15 μM. Compound 3 was then tested in rats for 4 days after oral dosing at 10, 30, and 100 mg/kg. Visibly yellow plasma at all doses alerted us to an increase in unconjugated bilirubin, and upon further investigation, significant inhibition of hUGT1A1 (IC 50 = 1.4 μM) and OATP1B1 (690 nM) was found. Furthermore, detailed tissue examination from the same study also revealed hepatocellular necrosis at all doses studied, which precluded a viable path forward for this compound.
It is widely recognized that high lipophilicity is associated with a greater chance of drug toxicity, 16 and in light of the profile of 3, we pursued a strategy of lowering cLogP. Reducing lipophilicity in CNS drugs can be particularly challenging since overly polar molecules generally fail to cross the blood−brain barrier, and many CNS targets often prefer lipophilic compounds. 17 Thus, balancing potency and polarity for CNS drugs in general, and GSMs in particular, is a well-recognized challenge. 18 After examining compounds from several subseries, we found that (S)-7-(4-fluorophenyl)-N 2 -(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N 4 -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine (4, BMS-932481) had the best balance of potency, efficacy, and offtarget profile (Table 1) .
Compound 4 differs from compound 3 primarily by changing the A-ring to the more polar 3-methyl triazole, which resulted in an increased free fraction (0.6%), consistent with our strategy. The Aβ 1−42 IC 50 of 4 was 6.6 nM, slightly less potent than 3, highlighting a trade-off between potency and polarity. Importantly, and consistent with the GSM mechanism, treatment of cultured H4-APPsw cells with 4 
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Letter resulted in a large decrease in Aβ 1−42 and Aβ 1−40 and a corresponding increase in Aβ 1−37 and Aβ 1−38 (Figure 2) as measured by mass spectrometry. Total Aβ 1−x was unchanged at concentrations of 4 up to 10 μM, as determined by Aβ 1−x ELISA. Furthermore, the same distribution among Aβ peptide species was recapitulated in both rat brain and CSF after intravenous administration of 4.
19 The amount of Aβ 1−42 in the brains of wild-type mice was reduced by 81% 3 h after a 30 mg/kg oral dose. In rats dosed orally at 10 mg/kg, brain Aβ 1−42 was reduced by 41% vs predose levels at the 5 h time point, with a concentration of 1.4 μM in plasma and a B/P ratio of 0.23. Compound 4 showed low clearance in rat (11.2 mL/ min/kg), with a volume of distribution of 2.3 L/kg and a halflife of 2.7 h (Table 2) . In preclinical species, oral bioavailability was 98%, 85%, and 45% in rat, dog, and cynomolgus monkey, respectively, when dosed as a nanosuspension. 20 Further testing in rats enabled generation of a PK/PD relationship fitted to an indirect response model. 21 When integrating over a 24 h time period, a 3 mg/kg dose reduced brain Aβ 1−42 AUC by 45% with an exposure of 9.7 μM·h, and a 10 mg/kg dose reduced brain Aβ 1−42 AUC by 66% with an exposure of 32 μM·h. Using these data, we calculated that a plasma exposure of 4.0 μM·h would achieve a 25% AUC reduction of Aβ 1−42 . Human PK was predicted by allometric scaling of PK results from rat, dog, and cynomolgus monkey. Combining the predicted human PK with the rat PK/PD forecasted that a total oral daily human dose of 110 mg (1.6 mg/kg) would result in a 31% reduction in brain Aβ 1−42 and that a 446 mg total daily dose would result in a 57% reduction in brain Aβ 1−42 . We observed a low peak-to-trough exposure profile, resulting in a predicted C max at the two doses of 0.32 and 1.3 μM, respectively. The projected human exposure calculations enabled interpretation of the metabolic profiling data.
Compound 4 inhibited recombinant CYP3A4 with an IC 50 of 0.51 μM after a 30 min incubation. A more comprehensive assay 22 was performed to assess the potential for timedependent inhibition of CYP3A4. The large K I of 82.5 μM mitigated the impact of a robust K inact of 0.47 min −1 , with the result indicating mild drug−drug interaction potential 23 due to CYP3A4 inhibition at the 110 mg (C max = 0.32 μM, 1000λ = 1.8 min ) doses. In human liver microsomes, the compound inhibited the activity of the CYP2C subfamily with single digit micromolar IC 50 s, and IC 50 s against the rest of the CYP isoforms tested were greater than 17 μM. PXR in vitro transactivation by compound 4 was evaluated to assess the potential for induction of CYP3A4-mediated metabolism, and 4 was found to have an EC 50 of >2.7 μM, with an average Y max of 36% (10 μM rifampicin = 100%). Following up on this result, CYP3A4 mRNA induction was assessed in cryopreserved primary human hepatocytes. A low (16%) elevation of CYP3A4 mRNA was observed at 1 μM, a concentration approximating the projected C max of 4, whereas a moderate (36−43%) elevation was observed at supra-physiological concentrations (3.3−10 μM). Taken together, these results supported further safety profiling. Cardiac safety was evaluated in multiple experiments. Compound 4 was 6-fold less potent at hERG than compound 3, a result we interpret as a consequence of its reduced lipophilicity. 24 Telemetry data from unconscious rabbits showed no change in QTcf and a 4 ms increase in QTcv after a 3 mg/kg dose (16 μM exposure). Dosing at 10 mg/kg (50 μM exposure) resulted in a 3 and 10 ms increase in QTcf and QTcv, respectively. The exposure multiples over the projected clinical C max were from 50-to 170-fold, consistent with a minimal risk of hERG liability. During these experiments, increased blood pressure and decreased heart rate were observed at doses of 10 mg/kg and higher; however, these effects were not seen in parallel experiments in conscious rats at any dose studied. The hemodynamic effects were attributed to the anesthesia used during the rabbit experiments.
Compound 4 was well tolerated in a 2-week oral repeat dose toxicity study in rats at 10, 30, and 100 mg/kg. A minimal, nontoxicologically significant bilirubin elevation was observed, in-line with previous observations in mice and in contrast to the results seen for 3. Subsequent in vitro profiling of bilirubin transporter inhibition revealed, surprisingly, that compound 4 had an identical potency at UGT1A1 (1.4 μM) to compound 3. Additionally, compound 4 potently inhibited the organic anion transporting polypeptide 1B1 (IC 50 = 66 nM). The lack of correlation between the potency at these transporters and the differential in vivo bilirubin levels observed in 3 and 4 is not currently understood; the hepatocellular necrosis uniquely observed with compound 3 may confound a simple interpretation. Findings from the two-week toxicity study were limited to stress and reduced food consumption effects for the high (100 mg/kg) oral dose group, with no Notchrelated goblet cell metaplasia in the duodenum, consistent with the gamma-secretase modulator mechanism of action. Additionally, no hepatotoxicity or necrosis was observed. Compound 4 showed a 48-fold margin over the projected human efficacious exposure of 4 μM·h at the NOAEL of 30 mg/kg. Additionally, an acute oral dose of 300 mg/kg in dogs was tolerated with no significant changes in bilirubin levels or other clinical pathological assessments. The observed C max and AUC in this experiment were 14 μM and 180 μM·h, respectively, translating to a 43-fold margin in C max and 46-fold in AUC to the projected efficacious clinical dose. Furthermore, in a one-month toxicity study in dogs, the high dose group showed a NOAEL to minimally significant hyperbilirubinemia at 150 mg/kg (40 μM·h exposure). In total, the toxicity profile supported the progression of compound 4 in human clinical trials.
Compound 3 was synthesized as shown in Scheme 1, starting with Grignard addition of phenylmagnesium bromide to cyclopentanone, followed by dehydration and oxidation to afford 2-phenyl cyclopentanone. Condensation with N-(chlorocarbonyl) isocyanate (CCI) 25 afforded compound 7 in low yield. Subsequent condensation with ammonia yielded the pyrimidine dione, which was then reacted with phosphoryl chloride to give dichloropyrimidine 8. Reaction with methylamine in THF gave a ∼4:1 ratio of monoaddition products favoring the desired 4-aminomethyl regioisomer 9. Aniline 11, derived from the substituted chloro-nitrobenzene 10 by nucleophilic aromatic substitution with chloroimidazole and subsequent reduction of the nitro group, was combined with 9 under acidic conditions to yield compound 3 after resolution by chiral HPLC.
As the program progressed, a more concise synthesis of the key pyrimidine dichloride was developed and used for the preparation of compound 4, as outlined in Scheme 2. Alkylation of ethyl p-fluorophenyl acetate 12 with ethyl-4-bromobutanoate afforded diester 13, which then formed the substituted cyclopentanone 14 via Dieckmann condensation. Reaction with molten urea directly provided the pyrimidine dione, which was taken forward in the previously described manner to penultimate 16. This route avoided the use of CCI, which was both toxic and of limited commercial supply. The yield of the final coupling with aniline 17 was improved by using catalytic sulfuric acid in NMP, which afforded the desired compound 4 after chiral chromatography. The absolute configuration of 4, as its HCl salt, was proven by X-ray diffraction. 26 The results from the phase 1 clinical trial of BMS-932481 have been reported. 27 Analysis of both plasma and CSF samples demonstrated a dose-dependent increase in Aβ 1−37 and Aβ 1−38 , a decrease in Aβ 1−42 and Aβ 1−40 , and no change in total Aβ 1−x after single oral doses of 10 to 1200 mg, and upon multiweek daily dosing at 50 to 200 mg. BMS-932481 was well tolerated when dosed acutely. ALT elevations were observed after administration of 200 mg of BMT-932481 for 24 days, which was hypothesized to be due to unexpected bioaccumulation of the drug in the liver. Modeling the multiple ascending dose data revealed that a ∼25% lowering of Aβ 1−42 would be achieved at an exposure deemed free of ALT elevation; however, the decision was made to discontinue the development of BMS-932481 due to the inability to safely escalate the dose to achieve greater Aβ reduction.
To summarize, we have discovered a bicyclic pyrimidine capable of modulating the activity of gamma-secretase to affect reduction in Aβ 1−42 and elevation of shorter Aβ peptides as a potential treatment for Alzheimer's disease. The acceptable projected human dose and attractive preclinical safety profile supported our decision to evaluate the clinical effect of a low Aβ 1−42 /Aβ 1−37/38 ratio in human subjects. A more detailed accounting of the broader medicinal chemistry efforts leading to the discovery of BMS-932481 will be reported in due course.
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